指南与共识妇科肿瘤

卵巢癌同源重组缺陷:全球专家共识关于检测及伴随诊断的比较

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.
指南 / 共识 · Eur J Cancer · 2024-12-09

该共识由99位来自31个国家的全球专家采用改良德尔菲法制定,基于系统文献检索及从研究者、公司和/或出版物获取的伴随诊断信息,旨在比较现有HRD伴随诊断并建立原发性和复发性卵巢癌HRD检测的全球专家共识。从15种可用的HRD伴随诊断中获得了14种(7种学术性;7种商业性)的技术信息,包括分析验证和临床验证,并就36项陈述达成共识。

要点

  • 99位来自31个国家的专家采用改良德尔菲法制定HRD检测共识。
  • 从15种可用HRD伴随诊断中获取14种(7种学术性;7种商业性)的技术信息。
  • 就36项陈述达成共识,涵盖HRD状态预测影响、验证要求、资源分层检测及未来方向。

核心结论

  • 该文稿提供了当前可用HRD伴随诊断的详细信息以及全球专家关于原发性和复发性卵巢癌患者HRD检测的最新指导。

研究设计与样本

  • 由99位来自31个不同国家的全球专家组成小组,采用改良德尔菲法,基于系统文献检索及从研究者、公司和/或出版物获取的伴随诊断信息,旨在建立共识陈述。

主要发现

  • 从15种可用的HRD伴随诊断中获得了14种(7种学术性;7种商业性)的技术信息,包括分析验证和临床验证。
  • 就36项陈述达成共识,涵盖以下主题:1)HRD状态对原发性和复发性卵巢癌中PARP抑制剂使用的预测影响;2)HRD伴随诊断的分析验证和临床验证要求;3)资源分层HRD检测;4)未来伴随诊断如何纳入额外方法以帮助解决未满足的检测需求。

关键数值与推荐

  • 就36项陈述达成共识,涵盖HRD状态对PARP抑制剂使用的预测影响、HRD伴随诊断的分析与临床验证要求、资源分层HRD检测以及未来伴随诊断方向。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD. However, the optimal HRD testing strategy is an area of debate. Moreover, recently published clinical and translational data may impact how HRD status may be used to identify patients likely to benefit from PARPi use. We aimed to extensively compare available HRD CDx and establish a worldwide expert consensus on HRD testing in primary and recurrent OC. METHODS: A group of 99 global experts from 31 different countries was formed. Using a modified Delphi process, the experts aimed to establish consensus statements based on a systematic literature search and CDx information sought from investigators, companies and/or publications. RESULTS: Technical information, including analytical and clinical validation, were obtained from 14 of 15 available HRD CDx (7 academic; 7 commercial). Consensus was reached on 36 statements encompassing the following topics: 1) the predictive impact of HRD status on PARPi use in primary and recurrent OC; 2) analytical and clinical validation requirements of HRD CDx; 3) resource-stratified HRD testing; and 4) how future CDx may include additional approaches to help address unmet testing needs. CONCLUSION: This manuscript provides detailed information on currently available HRD CDx and up-to-date guidance from global experts on HRD testing in patients with primary and recurrent OC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Quesada S, Penault-Llorca F, Matias-Guiu X, et al. Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics. Eur J Cancer. 2024. PMID: 39693891. doi:10.1016/j.ejca.2024.115169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。